Observational study of characteristics and clinical outcomes of Dutch patients with tuberous sclerosis complex and renal angiomyolipoma treated with everolimus

Differentiating the mTOR inhibitors everolimus and sirolimus in the treatment of tuberous sclerosis complex

(2015) Jeffrey P. MacKeigan et al.   NEURO-ONCOLOGY

The effect of everolimus on renal angiomyolipoma in patients with tuberous sclerosis complex being treated for subependymal giant cell astrocytoma: subgroup results from the randomized, placebo-controlled, Phase 3 trial EXIST-1

(2014) J. C. Kingswood et al.   NEPHROLOGY DIALYSIS TRANSPLANTATION

Patterns of renal angiomyolipoma regression post embolisation on medium- to long-term follow-up

(2013) K Patatas et al.   BRITISH JOURNAL OF RADIOLOGY

Everolimus for angiomyolipoma associated with tuberous sclerosis complex or sporadic lymphangioleiomyomatosis (EXIST-2): a multicentre, randomised, double-blind, placebo-controlled trial

(2013) John J Bissler et al.   LANCET

Decreased MicroRNA Is Involved in the Vascular Remodeling Abnormalities in Chronic Kidney Disease (CKD)

(2013) Neal X. Chen et al.   PLoS One

Kidney damage due to tuberous sclerosis complex: Management recommendations

(2013) O. Rouvière et al.   Diagnostic and Interventional Imaging

mTOR Inhibitors in Tuberous Sclerosis Complex

(2012) Paolo Curatolo et al.   Current Neuropharmacology

Introduction of the CKD-EPI equation to estimate glomerular filtration rate in a Caucasian population

(2011) J. A. J. G. van den Brand et al.   NEPHROLOGY DIALYSIS TRANSPLANTATION

Trends of Presentation and Clinical Outcome of Treated Renal Angiomyolipoma

(2010) Kyo Chul Koo et al.   YONSEI MEDICAL JOURNAL